DAVIS ROBERT T. JR.
Known title: EVP & President, TTCIK: 0001563606
Associated companies
Transaction History
| IART | ▼ Sell | Tax Withholding | 8,487 | $82K | 3/11/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 687 | $7K | 3/10/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 472 | $11K | 3/11/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 907 | $22K | 3/11/2025 | View on chart |
| IART | ▲ Buy | Grant | 12,425 | $0 | 3/11/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 592 | $13K | 3/10/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 443 | $16K | 3/12/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,581 | $57K | 3/12/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 458 | $17K | 3/11/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,952 | $71K | 3/11/2024 | View on chart |
| IART | ▲ Buy | Grant | 6,478 | $0 | 3/11/2024 | View on chart |
| IART | ▲ Buy | Grant | 13,805 | $0 | 3/11/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 635 | $23K | 3/10/2024 | View on chart |
| IART | ▲ Buy | Option Exercise | 8,736 | $285K | 3/6/2024 | View on chart |
| IART | ▼ Sell | Open Market | 8,348 | $305K | 3/6/2024 | View on chart |
| IART | ▲ Buy | Grant | 3,721 | $0 | 2/20/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 459 | $24K | 3/13/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,010 | $53K | 3/13/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 429 | $23K | 3/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 453 | $24K | 3/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 755 | $40K | 3/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 458 | $24K | 3/11/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 799 | $42K | 3/11/2023 | View on chart |
| IART | ▲ Buy | Grant | 4,227 | $0 | 3/10/2023 | View on chart |
| IART | ▲ Buy | Option Exercise | 1,566 | $42K | 3/1/2023 | View on chart |
| IART | ▼ Sell | Open Market | 1,566 | $86K | 3/1/2023 | View on chart |
| IART | ▲ Buy | Grant | 2,379 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,067 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,779 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,883 | $0 | 2/13/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 335 | $22K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 297 | $19K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 811 | $53K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,080 | $70K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 277 | $18K | 3/12/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,109 | $72K | 3/12/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 665 | $43K | 3/12/2022 | View on chart |
| IART | ▲ Buy | Grant | 3,269 | $0 | 3/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 4,608 | $0 | 3/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 2,956 | $0 | 2/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 3,936 | $0 | 2/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 6,466 | $0 | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15
Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.